Basal Cell Carcinoma (BCC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Basal Cell Carcinoma (BCC) (also called basal cell skin cancer) is generally defined as a locally invasive, slowly spreading tumor that rarely metastasizes, arising in the epidermis or hair follicles. The main etiological factor responsible for BCC is chronic UV exposure at the expense mostly of UVB rays with a length of 290-320 mm. This results in activating proto-oncogenes and inactivating tumor-suppressive genes in the keratinocytes.
·
Basal Cell Carcinoma (BCC) is quite common,
and the number of reported cases in the U.S. has steadily increased. The
incidence of BCC is about 2000 cases per 100 000 population. More than 4
million Americans are diagnosed with BCC each year.
Thelansis’s “Basal Cell Carcinoma
(BCC) Market Outlook, Epidemiology,
Competitive Landscape, and Market Forecast Report – 2021 To
2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Basal Cell Carcinoma (BCC) treatment
modalities options for eight major markets (USA, Germany, France, Italy, Spain,
UK, Japan, and China).
KOLs insights
of Basal Cell Carcinoma (BCC) across the 8 MM market from the centre of
Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm, and Unmet needs.
Basal Cell Carcinoma (BCC) Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment